Clinical trial · Interventional
wXELIRI Versus FOLFIRI Regimen in the Treatment of Advanced Colorectal Cancer Patients
A Multicenter, Randomized Phase II Study of Weekly XELIRI Regimen Versus FOLFIRI in the Treatment of Advanced Colorectal Cancer Patients
NCT01736904CI-TRIAL-00008554unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to compare weekly-XELIRI(wXELIRI) regimen versus FOLFIRI regimen in the treatment of advanced colorectal cancer patients. The hypothesis is the efficacy of wXELIRI is not less than FOLFIRI with tolerable toxicity.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| FOLFIRI regimen | Drug | FOLFIRI Regimen | ALIAS |
| wXELIRI regimen | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- FOLFIRI
- description
- FOLFIRI regimen
- interventionNames
- Drug: FOLFIRI regimen
- type
- EXPERIMENTAL
- label
- wXELIRI regimen
- description
- wXELIRI
- interventionNames
- Drug: wXELIRI regimen
Primary outcomes (1)
- measure
- Progression free survival which is calculated from the start of treatment to disease progression or death
- timeFrame
- eight weeks
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Second-line treatment for advanced colorectal cancer,irinotecan was not previously used. * Age range 18-70 years old * ECOG performance status 0-1 * Life expectancy of more than 3 months * Adequate organ function Exclusion Criteria: * Previous serious cardiac disease * History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix * Pregnant or lactating women * chronic inflammatory bowel disease or intestinal obstruction * Serious uncontrolled diseases and intercurrent infection
References
Publications (0)
Data not yet available
No reference posted for this study.